Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Entire COX-2 Class Is TARGET Of Critical Lancet Editorial

Aug 19 2004

• By Lee Kalowski

Related Content

Merck Arcoxia User Fee Date Is Nov. 13; Schering’s Late Fees For Zetia Delay Review

Feb 27 2004

Merck Raises Vioxx, Arcoxia Guidance To $2.8 Bil.-$3 Bil. For 2004

Jul 21 2004

Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis

Aug 19 2004

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window